HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
Fibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms. Accumulating evidence indicates that epigenetic alterations, including histone acetylation, play a pivotal role in this process. Histone acetylation...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-07-01
|
| Series: | Therapeutic Advances in Chronic Disease |
| Online Access: | https://doi.org/10.1177/2040622319862697 |
| _version_ | 1818924381624074240 |
|---|---|
| author | Xing Lyu Min Hu Jieting Peng Xiangyu Zhang Yan Y Sanders |
| author_facet | Xing Lyu Min Hu Jieting Peng Xiangyu Zhang Yan Y Sanders |
| author_sort | Xing Lyu |
| collection | DOAJ |
| description | Fibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms. Accumulating evidence indicates that epigenetic alterations, including histone acetylation, play a pivotal role in this process. Histone acetylation is governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are enzymes that remove the acetyl groups from both histone and nonhistone proteins. Aberrant HDAC activities are observed in fibrotic diseases, including cardiac and pulmonary fibrosis. HDAC inhibitors (HDACIs) are molecules that block HDAC functions. HDACIs have been studied extensively in a variety of tumors. Currently, there are four HDACIs approved by the US Food and Drug Administration for cancer treatment yet none for fibrotic diseases. Emerging evidence from in vitro and in vivo preclinical studies has presented beneficial effects of HDACIs in preventing or reversing fibrogenesis. In this review, we summarize the latest findings of the roles of HDACs in the pathogenesis of cardiac and pulmonary fibrosis and highlight the potential applications of HDACIs in these two fibrotic diseases. |
| first_indexed | 2024-12-20T02:24:26Z |
| format | Article |
| id | doaj.art-2fa325bb3d3343fb99c53a72af0c2031 |
| institution | Directory Open Access Journal |
| issn | 2040-6231 |
| language | English |
| last_indexed | 2024-12-20T02:24:26Z |
| publishDate | 2019-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Chronic Disease |
| spelling | doaj.art-2fa325bb3d3343fb99c53a72af0c20312022-12-21T19:56:45ZengSAGE PublishingTherapeutic Advances in Chronic Disease2040-62312019-07-011010.1177/2040622319862697HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosisXing LyuMin HuJieting PengXiangyu ZhangYan Y SandersFibrosis usually results from dysregulated wound repair and is characterized by excessive scar tissue. It is a complex process with unclear mechanisms. Accumulating evidence indicates that epigenetic alterations, including histone acetylation, play a pivotal role in this process. Histone acetylation is governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). HDACs are enzymes that remove the acetyl groups from both histone and nonhistone proteins. Aberrant HDAC activities are observed in fibrotic diseases, including cardiac and pulmonary fibrosis. HDAC inhibitors (HDACIs) are molecules that block HDAC functions. HDACIs have been studied extensively in a variety of tumors. Currently, there are four HDACIs approved by the US Food and Drug Administration for cancer treatment yet none for fibrotic diseases. Emerging evidence from in vitro and in vivo preclinical studies has presented beneficial effects of HDACIs in preventing or reversing fibrogenesis. In this review, we summarize the latest findings of the roles of HDACs in the pathogenesis of cardiac and pulmonary fibrosis and highlight the potential applications of HDACIs in these two fibrotic diseases.https://doi.org/10.1177/2040622319862697 |
| spellingShingle | Xing Lyu Min Hu Jieting Peng Xiangyu Zhang Yan Y Sanders HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis Therapeutic Advances in Chronic Disease |
| title | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| title_full | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| title_fullStr | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| title_full_unstemmed | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| title_short | HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| title_sort | hdac inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis |
| url | https://doi.org/10.1177/2040622319862697 |
| work_keys_str_mv | AT xinglyu hdacinhibitorsasantifibroticdrugsincardiacandpulmonaryfibrosis AT minhu hdacinhibitorsasantifibroticdrugsincardiacandpulmonaryfibrosis AT jietingpeng hdacinhibitorsasantifibroticdrugsincardiacandpulmonaryfibrosis AT xiangyuzhang hdacinhibitorsasantifibroticdrugsincardiacandpulmonaryfibrosis AT yanysanders hdacinhibitorsasantifibroticdrugsincardiacandpulmonaryfibrosis |